tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hutchmed Reports Strong 2024 Growth and Profitability
PremiumCompany AnnouncementsHutchmed Reports Strong 2024 Growth and Profitability
4M ago
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
Premium
The Fly
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
4M ago
Hutchmed reports FY24 EPS 22c vs. 59c last year
Premium
The Fly
Hutchmed reports FY24 EPS 22c vs. 59c last year
4M ago
Hutchmed announces NMPA approval for Orpathys supplemental new drug application
PremiumThe FlyHutchmed announces NMPA approval for Orpathys supplemental new drug application
6M ago
Hutchmed price target lowered to $26 from $30 at BofA
Premium
The Fly
Hutchmed price target lowered to $26 from $30 at BofA
6M ago
Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
Premium
The Fly
Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
6M ago
Hutchmed announces Elunate, Tyvyt NDA granted approval in China
PremiumThe FlyHutchmed announces Elunate, Tyvyt NDA granted approval in China
7M ago
Hutchmed to receive milestone payment following Takeda launch of Fruzaqla
Premium
The Fly
Hutchmed to receive milestone payment following Takeda launch of Fruzaqla
8M ago
Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial
Premium
The Fly
Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100